This PDF is the current document as it appeared on Public Inspection on 09/16/2013 at 08:45 am.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during August 2013. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable.
This rule is effective September 17, 2013.Start Further Info
FOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, email@example.com.End Further Info End Preamble Start Supplemental Information
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during August 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
|NADA/ANADA||Sponsor||New Animal Drug Product Name||Action||21 CFR Section||FOIA Summary||NEPA Review|
|200-514||Phibro Animal Health Corp., GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666||BOVIPROL (amprolium) 9.6% Oral Solution||Original approval as a generic copy of NADA 13-149||520.100||Yes||CE 1.|
|200-550||Ceva Sante Animale, 10 Avenue de la Ballastiére 33500 Libourne, France||MELOXIDYL (meloxicam) Oral Suspension||Original approval as a generic copy of NADA 141-213||520.1350||Yes||CE 1.|
|1 The Agency has determined under 21 CFR 25.33(a)(1) that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment.|
List of Subjects in 21 CFR Part 520End List of Subjects
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:Start Part
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part Start Amendment Part
2. In § 520.100, revise paragraph (b)(2) to read as follows:End Amendment Part
(b) * * *
(2) No. 066104 for use of product described in paragraph (a)(1) of this section as in paragraph (d) of this section.
3. Redesignate § 520.1350 as § 520.1367.End Amendment Part Start Amendment Part
4. Amend newly redesignated § 520.1367 by revising paragraphs (a) and (b) to read as follows:End Amendment Part
(a) Specifications—(1) Each milliliter of suspension contains 0.5 milligrams (mg) meloxicam.
(2) Each milliliter of suspension contains 1.5 mg meloxicam.
(b) Sponsors. See sponsors in § 510.600(c) of this chapter for uses as in paragraph (c) of this section:
(1) No. 000010 for use of the products described in paragraph (a) of this section; and
(2) No. 013744 for use of the product described in paragraph (a)(2) of this section.
Dated: September 11, 2013.
Director, Center for Veterinary Medicine.
[FR Doc. 2013-22523 Filed 9-16-13; 8:45 am]
BILLING CODE 4160-01-P